AcaHealth Pharma & Biotech Co.,LTD

長安醫藥生技 Innovative R&D

Chronic kidney diseases

Advantage of AH-401-CKD :
Novel mechanism commend as large unmet medical need from reviewer of top Journal.
AH-401-CKD is an EPO inducer for activating mitochondrial biogenesis & hemoglobin production.
AH-401-CKD is effective not only in chronic kidney disease, but also in chemotherapy-induced kidney failure and diabetes-related kidney failure.
mice model
Global market for chronic Kidney disease
Research and Markets Sep 15, 2017
The global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 12.4 Bn in 2016, and is expected to reach US$ 17.4 Bn by 2025. Medicines cannot reverse CKD, however they are used to treat complications and to slow further kidney damage. Factors such as rising incidence of cardiovascular disorders and diabetes, increasing geriatric population, significant unmet needs.
CKD News 2017 June
European physicians list DN as the kidney-disease area with the greatest unmet need, while U.S. physicians rank chronic kidney disease and obesity slightly higher.
Copyright © 2020 長安醫藥生技 AcaHealth Pharma & Biotech Company

WebMake SiteBuild | HiYP B2B Service | TaiwanDNS